Cell and Tissue Banking

, Volume 14, Issue 1, pp 33–44 | Cite as

Osteoconductivity and osteoinductivity of NanoFUSE® DBM

  • James F. Kirk
  • Gregg Ritter
  • Chad Waters
  • Sonoko Narisawa
  • José Luis Millán
  • James D. Talton
Original Paper


Bone graft substitutes have become an essential component in a number of orthopedic applications. Autologous bone has long been the gold standard for bone void fillers. However, the limited supply and morbidity associated with using autologous graft material has led to the development of many different bone graft substitutes. Allogeneic demineralized bone matrix (DBM) has been used extensively to supplement autograft bone because of its inherent osteoconductive and osteoinductive properties. Synthetic and natural bone graft substitutes that do not contain growth factors are considered to be osteoconductive only. Bioactive glass has been shown to facilitate graft containment at the operative site as well as activate cellular osteogenesis. In the present study, we present the results of a comprehensive in vitro and in vivo characterization of a combination of allogeneic human bone and bioactive glass bone void filler, NanoFUSE® DBM. NanoFUSE® DBM is shown to be biocompatible in a number of different assays and has been cleared by the FDA for use in bone filling indications. Data are presented showing the ability of the material to support cell attachment and proliferation on the material thereby demonstrating the osteoconductive nature of the material. NanoFUSE® DBM was also shown to be osteoinductive in the mouse thigh muscle model. These data demonstrate that the DBM and bioactive glass combination, NanoFUSE® DBM, could be an effective bone graft substitute.


Demineralized bone matrix Bioactive glass Osteoconductivity Osteoinductivity 



The authors would like to thank the donors and their families for their selfless gift of tissue donation, without which this research would not have been possible. The authors would also like to thank Nanotherapeutics, Inc. for their continued support of this research.


  1. Berven S, Tay BK, Kleinstueck FS, Bradford DS (2001) Clinical applications of bone graft substitutes in spine surgery: consideration of mineralized and demineralized preparations and growth factor supplementation. Eur Spine J 10(Suppl 2):S169–S177. doi: 10.1007/s005860100270 PubMedGoogle Scholar
  2. Biswas D, Bible JE, Whang PG, Miller CP, Jaw R, Miller S, Grauer JN (2010) Augmented demineralized bone matrix: a potential alternative for posterolateral lumbar spinal fusion. Am J Orthop 39(11):531–538PubMedGoogle Scholar
  3. Cornell CN (1999) Osteoconductive materials and their role as substitutes for autogenous bone grafts. Orthop Clin North Am 30(4):591–598PubMedCrossRefGoogle Scholar
  4. Edwards JT, Diegmann MH, Scarborough NL (1998) Osteoinduction of human demineralized bone: characterization in a rat model. Clin Orthop Relat Res 357:219–228PubMedCrossRefGoogle Scholar
  5. Fujishiro Y, Hench LL, Oonishi H (1997) Quantitative rates of in vivo bone generation for Bioglass and hydroxyapatite particles as bone graft substitute. J Mater Sci Mater Med 8(11):649–652PubMedCrossRefGoogle Scholar
  6. Glowacki J, Kaban LB, Murray JE, Folkman J, Mulliken JB (1981) Application of the biological principle of induced osteogenesis for craniofacial defects. Lancet 1(8227):959–962PubMedCrossRefGoogle Scholar
  7. Goulet JA, Senunas LE, DeSilva GL, Greenfield ML (1997) Autogenous iliac crest bone graft. Complications and functional assessment. Clin Orthop Relat Res 339:76–81PubMedCrossRefGoogle Scholar
  8. Hattar S, Berdal A, Asselin A, Loty S, Greenspan DC, Sautier JM (2002) Behaviour of moderately differentiated osteoblast-like cells cultured in contact with bioactive glasses. Eur Cells Mater 4:61–69Google Scholar
  9. Heary RF, Schlenk RP, Sacchieri TA, Barone D, Brotea C (2002) Persistent iliac crest donor site pain: independent outcome assessment. Neurosurgery 50(3):510–516 discussion 516–517PubMedGoogle Scholar
  10. Hench LL, Paschall HA (1973) Direct chemical bond of bioactive glass-ceramic materials to bone and muscle. J Biomed Mater Res 7(3):25–42. doi: 10.1002/jbm.820070304 PubMedCrossRefGoogle Scholar
  11. Hench LL, Xynos ID, Polak JM (2004) Bioactive glasses for in situ tissue regeneration. J Biomater Sci Polym Ed 15(4):543–562PubMedCrossRefGoogle Scholar
  12. Hoylaerts MF, Ding L, Narisawa S, Van Kerckhoven S, Millan JL (2006) Mammalian alkaline phosphatase catalysis requires active site structure stabilization via the N-terminal amino acid microenvironment. Biochemistry 45(32):9756–9766. doi: 10.1021/bi052471+ PubMedCrossRefGoogle Scholar
  13. Ito G, Matsuda T, Inoue N, Kamegai T (1987) A histological comparison of the tissue interface of bioglass and silica glass. J Biomed Mater Res 21(4):485–497. doi: 10.1002/jbm.820210408 PubMedCrossRefGoogle Scholar
  14. Kasten P, Luginbuhl R, van Griensven M, Barkhausen T, Krettek C, Bohner M, Bosch U (2003) Comparison of human bone marrow stromal cells seeded on calcium-deficient hydroxyapatite, beta-tricalcium phosphate and demineralized bone matrix. Biomaterials 24(15):2593–2603PubMedCrossRefGoogle Scholar
  15. Kitsugi T, Nakamura T, Yamamura T, Kokubu T, Shibuya T, Takagi M (1987) SEM-EPMA observation of three types of apatite-containing glass-ceramics implanted in bone: the variance of a Ca-P-rich layer. J Biomed Mater Res 21(10):1255–1271. doi: 10.1002/jbm.820211008 PubMedCrossRefGoogle Scholar
  16. Kokubo T, Ito S, Huang ZT, Hayashi T, Sakka S, Kitsugi T, Yamamuro T (1990) Ca, P-rich layer formed on high-strength bioactive glass-ceramic A-W. J Biomed Mater Res 24(3):331–343. doi: 10.1002/jbm.820240306 PubMedCrossRefGoogle Scholar
  17. Logeart-Avramoglou D, Anagnostou F, Bizios R, Petite H (2005) Engineering bone: challenges and obstacles. J Cell Mol Med 9(1):72–84PubMedCrossRefGoogle Scholar
  18. Mauney JR, Blumberg J, Pirun M, Volloch V, Vunjak-Novakovic G, Kaplan DL (2004a) Osteogenic differentiation of human bone marrow stromal cells on partially demineralized bone scaffolds in vitro. Tissue Eng 10(1–2):81–92. doi: 10.1089/107632704322791727 PubMedCrossRefGoogle Scholar
  19. Mauney JR, Sjostorm S, Blumberg J, Horan R, O’Leary JP, Vunjak-Novakovic G, Volloch V, Kaplan DL (2004b) Mechanical stimulation promotes osteogenic differentiation of human bone marrow stromal cells on 3-D partially demineralized bone scaffolds in vitro. Calcif Tissue Int 74(5):458–468. doi: 10.1007/s00223-003-0104-7 PubMedCrossRefGoogle Scholar
  20. Morone MA, Boden SD (1998) Experimental posterolateral lumbar spinal fusion with a demineralized bone matrix gel. Spine (Phila Pa 1976) 23(2):159–167CrossRefGoogle Scholar
  21. Mulliken JB, Glowacki J, Kaban LB, Folkman J, Murray JE (1981) Use of demineralized allogeneic bone implants for the correction of maxillocraniofacial deformities. Ann Surg 194(3):366–372PubMedCrossRefGoogle Scholar
  22. Mulliken JB, Kaban LB, Glowacki J (1984) Induced osteogenesis—the biological principle and clinical applications. J Surg Res 37(6):487–496PubMedCrossRefGoogle Scholar
  23. Narisawa S, Hofmann MC, Ziomek CA, Millan JL (1992) Embryonic alkaline phosphatase is expressed at M-phase in the spermatogenic lineage of the mouse. Development 116(1):159–165PubMedGoogle Scholar
  24. Oonishi H, Kushitani S, Yasukawa E, Iwaki H, Hench LL, Wilson J, Tsuji E, Sugihara T (1997) Particulate bioglass compared with hydroxyapatite as a bone graft substitute. Clin Orthop Relat Res 334:316–325PubMedCrossRefGoogle Scholar
  25. Rosenthal RK, Folkman J, Glowacki J (1999) Demineralized bone implants for nonunion fractures, bone cysts, and fibrous lesions. Clin Orthop Relat Res 364:61–69PubMedCrossRefGoogle Scholar
  26. Sassard WR, Eidman DK, Gray PM, Block JE, Russo R, Russell JL, Taboada EM (2000) Augmenting local bone with Grafton demineralized bone matrix for posterolateral lumbar spine fusion: avoiding second site autologous bone harvest. Orthopedics 23(10):1059–1064 discussion 1064–1055PubMedGoogle Scholar
  27. Tiedeman JJ, Garvin KL, Kile TA, Connolly JF (1995) The role of a composite, demineralized bone matrix and bone marrow in the treatment of osseous defects. Orthopedics 18(12):1153–1158PubMedGoogle Scholar
  28. Ubhi CS, Morris DL (1984) Fracture and herniation of bowel at bone graft donor site in the iliac crest. Injury 16(3):202–203PubMedCrossRefGoogle Scholar
  29. Urist MR, Dowell TA (1968) Inductive substratum for osteogenesis in pellets of particulate bone matrix. Clin Orthop Relat Res 61:61–78PubMedCrossRefGoogle Scholar
  30. Urist MR, Strates BS (1970) Bone formation in implants of partially and wholly demineralized bone matrix. Including observations on acetone-fixed intra and extracellular proteins. Clin Orthop Relat Res 71:271–278PubMedCrossRefGoogle Scholar
  31. Urist MR, DeLange RJ, Finerman GA (1983) Bone cell differentiation and growth factors. Science 220(4598):680–686PubMedCrossRefGoogle Scholar
  32. Wheeler DL, Stokes KE, Hoellrich RG, Chamberland DL, McLoughlin SW (1998) Effect of bioactive glass particle size on osseous regeneration of cancellous defects. J Biomed Mater Res 41(4):527–533. doi: 10.1002/(SICI)1097-4636(19980915)41:4<527:AID-JBM3>3.0.CO;2-E PubMedCrossRefGoogle Scholar
  33. Wheeler DL, Eschbach EJ, Hoellrich RG, Montfort MJ, Chamberland DL (2000) Assessment of resorbable bioactive material for grafting of critical-size cancellous defects. J Orthop Res 18(1):140–148. doi: 10.1002/jor.1100180120 PubMedCrossRefGoogle Scholar
  34. Wilson J, Pigott GH, Schoen FJ, Hench LL (1981) Toxicology and biocompatibility of bioglasses. J Biomed Mater Res 15(6):805–817. doi: 10.1002/jbm.820150605 PubMedCrossRefGoogle Scholar
  35. Xynos ID, Edgar AJ, Buttery LD, Hench LL, Polak JM (2000a) Ionic products of bioactive glass dissolution increase proliferation of human osteoblasts and induce insulin-like growth factor II mRNA expression and protein synthesis. Biochem Biophys Res Commun 276(2):461–465. doi: 10.1006/bbrc.2000.3503 PubMedCrossRefGoogle Scholar
  36. Xynos ID, Hukkanen MV, Batten JJ, Buttery LD, Hench LL, Polak JM (2000b) Bioglass 45S5 stimulates osteoblast turnover and enhances bone formation In vitro: implications and applications for bone tissue engineering. Calcif Tissue Int 67(4):321–329. doi: 10.1007/s002230001134 PubMedCrossRefGoogle Scholar
  37. Xynos ID, Edgar AJ, Buttery LD, Hench LL, Polak JM (2001) Gene-expression profiling of human osteoblasts following treatment with the ionic products of Bioglass 45S5 dissolution. J Biomed Mater Res 55(2):151–157. doi: 10.1002/1097-4636(200105)55:2<151:AID-JBM1001>3.0.CO;2-D PubMedCrossRefGoogle Scholar
  38. Younger EM, Chapman MW (1989) Morbidity at bone graft donor sites. J Orthop Trauma 3(3):192–195PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • James F. Kirk
    • 1
  • Gregg Ritter
    • 1
  • Chad Waters
    • 1
  • Sonoko Narisawa
    • 2
  • José Luis Millán
    • 2
  • James D. Talton
    • 1
  1. 1.Research and Development DepartmentNanotherapeutics, Inc.AlachuaUSA
  2. 2.Sanford-Burnham Medical Research InstituteLa JollaUSA

Personalised recommendations